Astrana Health, Inc. (ASTH) Stock Analysis

Company Overview

Astrana Health, Inc. functions as a healthcare management company that delivers medical care services across the United States through three distinct operational segments: Care Partners, Care Delivery, and Care Enablement. The enterprise operates within the broader Healthcare sector, specifically classified under the Medical Care Facilities industry, which encompasses organizations providing direct patient care and related support services. This entity manages a substantial workforce of 3,000 employees and maintains a market capitalization of $1.34B, reflecting its significant footprint in the regional and national healthcare landscape. The reported annual revenue of $3.18B further contextualizes the company's scale, indicating a large, established operation that generates billions in top-line sales while employing a significant labor force to execute its care coordination and delivery models.

Financial Health

The company reports a trailing twelve-month revenue of $3.18B with a net income of $22.49M and an EBITDA of $143.87M. The substantial disparity between the $3.18B revenue figure and the $22.49M net income highlights a cost structure where operating expenses, likely driven by labor-intensive service delivery and regulatory compliance, consume the majority of top-line earnings before reaching the bottom line. Astrana Health generates $227.95M in free cash flow, a metric that underscores the company's ability to generate liquidity from its core operations despite its high revenue requirements, providing financial flexibility for capital allocation. Three margin metrics further detail the profitability profile: a gross margin of 10.7% indicates low gross efficiency typical of service-based industries, an operating margin of 1.9% reveals the pressure of overhead costs, and a profit margin of 0.7% demonstrates the extreme thinness of the final earnings relative to sales. The balance sheet shows a cash position of $429.59M against total debt of $1.08B, resulting in a debt-to-equity ratio of 193.10 which characterizes the capital structure as highly leveraged rather than conservative. Liquidity is supported by a current ratio of 1.40, suggesting the company holds sufficient current assets to cover its short-term obligations without immediate distress. Return on equity stands at 4.5% while return on assets is 3.4%, metrics that collectively indicate the effectiveness of management in generating returns relative to the shareholders' equity and the total asset base utilized.

Valuation Assessment

Valuation multiples for Astrana Health include a trailing P/E ratio of 52.22 and a forward P/E of 8.03, a dramatic divergence that implies the market expects a massive expansion in earnings growth that would be required to justify the current historical multiple. The price-to-book ratio is 1.51, indicating that the market values the company at a premium of 51% over its net book value, suggesting confidence in assets not fully reflected on the balance sheet or intangible value. Alternative valuation metrics provide additional perspective, with a price-to-sales ratio of 0.42 and an EV/EBITDA of 11.23, figures that suggest the stock is priced on a revenue basis that is relatively low but an enterprise value relative to cash flow that is moderate for a leveraged healthcare operator. Technical trading ranges are bounded by a 52-week high of $34.80 and a 52-week low of $18.08, meaning the current trading price sits at a specific point within this volatility range relative to recent market performance. The stock exhibits a beta of 0.90, indicating that its price volatility moves in tandem with the broader market but with slightly less sensitivity, making it a proxy investment with market-matching risk characteristics.

Growth & Income

Revenue growth for the trailing twelve months stands at 42.9%, while earnings growth is listed as N/A, a condition that implies earnings are not currently expanding at a rate that can be quantified against the recent year or that historical earnings are too thin to yield a meaningful percentage change for comparison. Because the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders, which implies the firm reinvests all available earnings back into the business for expansion or operational improvement rather than paying out income. This non-dividend profile means the primary return mechanism relies entirely on capital appreciation rather than income generation, distinguishing its income profile from peer companies that utilize payouts to reward investors. The overall growth and income profile is characterized by high top-line expansion coupled with a lack of cash return to shareholders, focusing the investment thesis strictly on the potential for future earnings scaling rather than current yield.